Kingmed key facts
- Developer of organoid solutions intended for the pharmaceutical industry.
- Notable investors include TopoScend Capital, Fuyang Yingke Fund Management, Boji Pharmaceutical Technology, Feixi County Industrial Park Investment Holding (Group), Jointown Pharmaceutical Group — 7 tracked in total.
- Status: Privately Held (backing).
- ·Watch Kingmed: the Monday email on marks, rounds and moves
Kingmed funding rounds
No funding rounds for Kingmed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Kingmed investors
7 investors are on record for Kingmed, including TopoScend Capital, Fuyang Yingke Fund Management, Boji Pharmaceutical Technology and Feixi County Industrial Park Investment Holding (Group).
About Kingmed
Developer of organoid solutions intended for the pharmaceutical industry. The company offers a product that mainly focuses on the organoid platform, integrates organoid biotechnology with precision medicine, pharmacy, bioengineering, artificial intelligence, and other multidisciplinary technologies to transform products and services, providing customers with valuable and innovative products.
- Sector
- Healthcare
- HQ
- Chongqing, China
- Founded
- 2019
- Employees
- 7
- Website
- kingmedpharm.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Kingmed doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.